Check for updates





Blood 142 (2023) 1909–1910

The 65th ASH Annual Meeting Abstracts

## POSTER ABSTRACTS

## 642.CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND EPIDEMIOLOGICAL

Toxicity, Progression-Free Survival, and Quality of Life of Patients Treated with Zanubrutinib Versus Ibrutinib: A Q-TWiST Analysis from the ALPINE Study in Relapsed or Refractory Chronic Lymphocytic Leukemia

Vincent Levy, MD PhD<sup>1</sup>, Tushar Srivastava<sup>2</sup>, Keri Yang, PhD MBA, MPH, MS, CPM, BSPharm<sup>3</sup>, Palash Purkayastha<sup>4</sup>, Raju Gautam<sup>2</sup>, Kaijun Wang<sup>3</sup>, Leyla Mohseninejad, PhD<sup>5</sup>

<sup>1</sup> Hôpital Avicenne, AP-HP et Université Sorbonne, Paris, France

<sup>2</sup>ConnectHEOR, London, United Kingdom

<sup>3</sup>BeiGene USA, Inc, San Mateo, CA

<sup>4</sup>ConnectHEOR, Delhi, India

<sup>5</sup>BeiGene Netherlands B.V., Schiphol, Netherlands

Introduction: Zanubrutinib is a second-generation Bruton's tyrosine kinase inhibitor (BTKi) with enhanced specificity over the first-generation BTKi ibrutinib. Patients treated with zanubrutinib had a significantly longer progression-free survival (PFS) versus those treated with ibrutinib in the global, phase 3, randomized ALPINE trial in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (NCT03734016).

Quality-adjusted time without symptoms of disease and toxicity (Q-TWiST) is a clinical tool to assess overall benefits and risks of cancer therapies by integrating progression, survival, treatment toxicity, and patient quality of life (QoL) into a single metric. It provides valuable insights into the quality and duration of improved health states. To gain a comprehensive understanding of the benefits and risks associated with zanubrutinib versus ibrutinib in terms of quality-adjusted survival, a Q-TWiST analysis was performed within the ALPINE trial.

Methods: Patients in the ALPINE trial were followed for a median duration of 29.6 months. For the Q-TWiST analysis, overall survival (OS) of each patient was partitioned into 3 mutually exclusive health states: TOX (time before disease progression with toxicity after randomization); TWiST (time from randomization to disease progression without toxicity); and REL (time after disease progression until death or censoring). Survival curves corresponding to TOX, PFS, and OS were estimated by Kaplan-Meier method with a monthly cycle. Restricted mean survival time for each health state was derived from the area under the Kaplan-Meier curve (TWiST = PFS - TOX; REL = OS - PFS). Q-TWiST for each treatment was estimated as the mean time spent in each health state weighted by its respective QoL, denoted by health states' utility value (U; 0 [indicates death] to 1.0 [indicates "perfect" health]). Relative Q-TWiST gain was estimated by dividing the absolute Q-TWiST gain by mean OS with ibrutinib.

To ensure the comparability of populations and treatments across published Q-TWiST studies, the base-case analysis focused on a high-risk population (i.e., patients with chromosome 17p deletion, *TP53* mutation, or both). In the base case, the TOX health state included adverse events (AEs) of grade 2 or higher. Standard utilities were applied, with a value of 0.5 assigned to both TOX and REL and a value of 1.0 assigned to TWiST. A sensitivity analysis was performed in an intent-to-treat population with same-grade AEs considered for TOX and standard utilities.

Results: In the base case, the mean durations of TOX, TWiST, and REL health states for zanubrutinib (N = 73) were 11.54 months, 14.45 months, and 1.70 months, respectively. The corresponding durations for ibrutinib (N = 71) were 11.38 months, 11.09 months, and 3.78 months, respectively. The mean difference (95% CI) for zanubrutinib versus ibrutinib was 0.16 months (-0.18, 0.51) for the TOX state, 3.36 months (2.6, 4.2) for the TWiST state, and -2.08 months (-2.6, -1.6) for the REL state. The mean duration of Q-TWiST was 21.07 months for zanubrutinib versus 18.67 months for ibrutinib. The estimated difference in means (95% CI) for Q-TWiST gain was significantly higher for zanubrutinib versus ibrutinib (2.40 months; 1.9, 2.9; P<0.001), and the relative Q-TWiST gain was 9.14% (Figure). In the sensitivity analysis, using the intent-to-treat population, the mean difference (95% CI) for Q-TWiST gain was 1.30 months (1.0, 1.6; P=0.05) for zanubrutinib versus ibrutinib, and the relative Q-TWiST gain was 4.63%.

Conclusions: This Q-TWiST analysis demonstrated a statistically significant gain in quality-adjusted survival with zanubrutinib compared with ibrutinib in patients with high-risk R/R CLL. The slightly longer TOX duration in patients receiving zanubrutinib versus those receiving ibrutinib could be explained in part by better treatment adherence. The results of this Q-TWiST analysis,

## POSTER ABSTRACTS

which integrates both the length and quality of survival in addition to efficacy and toxicity, provide valuable insights that may help to inform clinical decision-making in the treatment of patients with R/R CLL.

**Disclosures Levy:** Amgen, Abbvie, AZ, Beigene, BMS, Dova/Sobi, Glead, Morphosys/Incyte, Seagen, Takeda, Karyoparms, pharmaEssentia, Genmab, Janssen, Sanofi: Consultancy, Honoraria, Speakers Bureau. **Yang:** BeiGene: Current Employment, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding. **Wang:** BeiGene: Current Employment, Current equity holder in publicly-traded company. The past 24 months; BeiGene: Current Employment, Current Employment, Current Employment, Current holder of stock options in a privately-held company.

## Physics: Q-19657 analysis results abouting prophing representation of TCR, 19657, and Mill. health states of CLL pathods traded with (4) membratistic and CD tradeds in ALPICE trial dates once analysis)



9-1967, gally-ajasia ina allant gaptan of dawa ani tabiy 196, ina dir dawa paganta adi dalidanang 1969, ina ka matatalar is dawa paganta allant tabiy 196, ina lalar dawa paganta alk tabiy dir antatalar. Is ina jum ana, 196 Indata alama panta d'anta 2 ortidae, ani davia i dir valate was pallat 8.5 TCK 1.6 TXCC ani 9.5 RC.

Figure 1

https://doi.org/10.1182/blood-2023-173540